Skip to main content
OpenTrials
Completed

NCT Number: NCT01190059

Normothermic Ex Vivo Lung Perfusion (EVLP) For An Improved Assessment of Donor Lungs For Transplantation

The use of ex vivo lung perfusion (EVLP) will allow for a secondary evaluation technique for donor lungs that fail to meet standard acceptability criteria. This advanced assessment might lead to increased utilization rates of donor lungs and improved outcomes after lung transplantation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Toronto General Hospital

Toronto, Ontario, M5G 1Z5, Canada

About this study

Human donor lungs that do not meet the standard clinical criteria for donor lung utilization but fit into the study inclusion criteria will be retrieved from the donor using current donor lung retrieval techniques.

These lungs will be brought to the study transplant center to be re-assessed by the transplant team. The lungs will be physiologically assessed during ex vivo perfusion with Steen Solution. Perfusion of these lungs will be performed using Steen solution with the addition of methylprednisolone, heparin and antibiotics. With respect to the decision of lung utilization those organs with a delta pO2 (Δ pO2 = Pulmonary vein pO2 - pulmonary artery pO2) during ex vivo perfusion assessment > 350mmHg, good lung compliance, and a favorable opinion of the transplant surgeon will be considered transplantable. Lungs will be excluded for transplantation: if the Δ pO2 is less than 350mmHg or if they demonstrate >10% deterioration in any of the following functional parameters: pulmonary vascular resistance (PVR), dynamic compliance or airway pressures. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for donor lung:

  • Recipient to undergo a single or bilateral Lung Transplantation
  • Last donor PaO2/FiO2 ≤ 300mmHg
  • Poor oxygenation and/or poor lung compliance is the primary reason for unsuitability
  • Absence of pneumonia, persistent purulent secretion on bronchoscopy or significant mechanical trauma

Exclusion criteria

  • Infection
  • Aspiration
  • Significant mechanical lung injury - contusion
  • Infectious diseases : HIV, Hepatitis B and C, HTLV & Syphilis
  • Malignancy

Treatment and study plan

Ex vivo lung perfusion with Steen Solution™

Drug

The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.

Primary outcomes

  1. PGD scores in the first 72 hours after lung transplantation.

    Time frame: 72 hours

    Immediate lung function is one of the key factors in determining the impact of donor lung quality, therefore the PGD score within 72 hrs was selected as the primary endpoint.

  2. 30 day Mortality

    Time frame: 30 days

    Mortality at 30 days post transplant

Secondary outcomes

  1. Extra-corporeal membrane oxygenation use

    Time frame: 30 days

    If the patient needed to be placed on extra-corporeal membrane oxygenation after transplantation.

  2. Bronchial complications

    Time frame: 30 days

    To see if there was an increased risk for bronchial complications

  3. Ventilator duration

    Time frame: 30 days

    How long was the patient on the ventilator after lung transplantation and was there an increased time on ventilator for the patient after EVLP.

  4. Intensive Care Unit length of stay

    Time frame: 30 days

  5. Hospital length of stay

    Time frame: 30 days

    Time in the hospital

Sponsors and collaborators

Lead sponsor

XVIVO Perfusion

Industry

Registry information

Acronym: HELP

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Aug 27, 2010
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.